Journal article
Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review
B Meiser, WKT Wong, M Peate, C Julian-Reynier, J Kirk, G Mitchell
HEREDITARY CANCER IN CLINICAL PRACTICE | BMC | Published : 2017
Abstract
BACKGROUND: Selective estrogen receptor modulators, such as tamoxifen, reduce breast cancer risk by up to 50% in women at increased risk for breast cancer. Despite tamoxifen's well-established efficacy, many studies show that most women are not taking up tamoxifen. This systematic literature review aimed to identify the motivators and barriers to tamoxifen use 's amongst high-risk women. METHODS: Using MEDLINE, PsycINFO, and Embase plus reviewing reference lists of relevant articles published between 1995 and 2016, 31 studies (published in 35 articles) were identified, which addressed high-risk women's decisions about risk-reducing medication to prevent breast cancer and were peer-reviewed p..
View full abstractRelated Projects (1)
Grants
Awarded by Cancer Council of New South Wales
Awarded by National Health and Medical Research Council Australia
Awarded by National Breast Cancer Foundation
Funding Acknowledgements
D This work was funded by a Strategic Partnership Grant from Cancer Council of New South Wales (ID SRP 13-02). Bettina Meiser is supported Senior Research Fellowship Level B (ID 1078523) from the National Health and Medical Research Council Australia. Michelle Peate is currently supported by a National Breast Cancer Foundation Early Career Fellowship (ECG-15-005).